- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04023214
The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease
Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Following recruitment we will record the following baseline demographics; age, gender, smoking status, body mass index, medical history.
Participants will undergo a noninvasive vascular assessment, venepuncture and will provide a urine sample.This will be done during a single visit to the CRF.
Noninvasive vascular assessment will consist of:
Peripheral Arterial Tonometry This will be measured using the EndoPAT system (Itamar Medical)
Endothelial shear stress flow stimulus will be provided by inflation of a blood pressure cuff around the upper non-dominant arm to suprasystolic pressure (but <300mmHg) for 5 minutes. Following release of the cuff the resulting digital microcirculation vasodilatory response to ischaemic hyperaemia, quantified as the pulse wave amplitude, will be monitored over 5 minutes. The peak pulse wave amplitude measured at 90-150s post cuff deflation relative to baseline will be indexed to the changes in the opposite arm to give the reactive hyperaemia index. This measure of endothelial function constitutes the outcome measure.
- Blood Pressure Assessment Brachial artery blood pressure will be measured in the left arm in the supine position using an automated device (Dinamap) and in accordance with the clinical research facility SOP.
- Blood samples and urine samples
Samples for plasma will be centrifuged and stored at -80C. Biochemical analysis will be performed by the laboratory of the STH NHS Trust for standard tests and by validated assays for non-routine markers (as detailed below) in the Academic Nephrology Unit.
Participants will be asked to collect a 24h urine sample from the day before the study visit and to provide a spot urine sample on the day. This will be analysed at the laboratory of the STH NHS Trust.
Biochemical Analysis
Serum samples will be analyzed for Full blood count, Urea, Electrolytes, Glucose, Insulin, Lipid Profile, Homocysteine, (Hs) CRP and Creatinine Levels.
Serum and plasma will also be stored for future analysis of relevant biomarkers of endothelial function or nitric oxide metabolism as indicated by preliminary results.
Urine samples will be analysed initially for protein creatinine ratio (PCR). The rest will be frozen for future analysis of urinary biomarkers of endothelial function or nitric oxide metabolism.
Undersøgelsestype
Tilmelding (Faktiske)
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Age >18yrs, <50yrs
- Able to understand spoken/written English sufficiently to give informed consent and to take part in clinical assessment
- Clinical diagnosis of ADPKD
- eGFR >60ml/min/1.73m2
Exclusion Criteria:
- No history of cardiovascular disease or hypertension
- Not diabetic
- Not smoking
- Not breastfeeding
- Not pregnant
- Not taking any regular medication (except oral contraceptives)
- No musculoskeletal conditions contraindicating inflation of a blood pressure cuff to suprasystolic pressures around the forearm (as part of EndoPAT measurements)
- Not morbidly obese: BMI<35 (May contribute to endothelial dysfunction)
- eGFR <60ml/min/1.73m2
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Kontrolelementer
Sunde frivillige
|
This will be measured using the EndoPAT system (Itamar Medical)
|
|
ADPKD
ADPKD patients
|
This will be measured using the EndoPAT system (Itamar Medical)
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Reactive hyperemia index (RHI)
Tidsramme: Baseline
|
EndoPAT values (Endoscore)
|
Baseline
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Systolic and diastolic Blood pressure
Tidsramme: Baseline
|
mm Hg
|
Baseline
|
|
Proteinuria
Tidsramme: Baseline
|
Protein creatinine ratio
|
Baseline
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Albert Ong, STH
- Studieleder: Timothy Chico, STH
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- STH15983
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Polycystisk nyre, autosomal dominant
-
Emory UniversityPKD FoundationAfsluttet
-
Mario Negri Institute for Pharmacological ResearchOtsuka Pharmaceutical Italy S.r.l.AfsluttetAutosomal dominant polycystisk nyresygdomItalien
-
CHU de ReimsAfsluttetAutosomal dominant polycystisk nyresygdomFrankrig
-
Otsuka Pharmaceutical Development & Commercialization...AfsluttetAutosomal dominant polycystisk nyresygdomForenede Stater
-
Regional Hospital HolstebroAarhus University HospitalAfsluttetAutosomal dominant polycystisk nyresygdomDanmark
-
University Hospital, BrestUkendtAutosomal dominant polycystisk nyresygdomFrankrig
-
Federico II UniversityAfsluttetAutosomal dominant polycystisk nyresygdom
-
Kyorin UniversityUkendt
-
Cambridge University Hospitals NHS Foundation TrustAddenbrookes Charitable Trust; PKD Charity; British Renal Society & British...AfsluttetAutosomal dominant polycystisk nyresygdomDet Forenede Kongerige
-
University of PittsburghNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) og andre samarbejdspartnereAfsluttetAutosomal dominant polycystisk nyresygdomForenede Stater